Eagle Soars As It Looks To 13-Year Head Start On Vasopressin In US
FDA Approves Eagle’s Vasostrict ANDA Product; Won Patent Trial In August
Following the disappointment of a complete response letter and delayed trial proceedings, Eagle has secured FDA approval for the first generic version of Par’s Vasostrict, which is tipped to have branded sales approaching $1bn in the US in 2021.
